>
Switch to:

Cara Therapeutics PB Ratio

: 3.17 (As of Today)
View and export this data going back to 2014. Start your Free Trial

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2021-10-20), Cara Therapeutics's share price is $12.89. Cara Therapeutics's Book Value per Share for the quarter that ended in Jun. 2021 was $4.06. Hence, Cara Therapeutics's PB Ratio of today is 3.17.

The historical rank and industry rank for Cara Therapeutics's PB Ratio or its related term are showing as below:

NAS:CARA' s PB Ratio Range Over the Past 10 Years
Min: 1.24   Med: 4.67   Max: 20.39
Current: 3.16

1.24
20.39

During the past 10 years, Cara Therapeutics's highest PB Ratio was 20.39. The lowest was 1.24. And the median was 4.67.

NAS:CARA's PB Ratio is ranked lower than
66% of the 270 Companies
in the Biotechnology industry.

( Industry Median: 4.30 vs. NAS:CARA: 3.16 )

During the past 12 months, Cara Therapeutics's average Book Value Per Share Growth Rate was 35.10% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 23.40% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 11.60% per year.

During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Cara Therapeutics was 29.10% per year. The lowest was -4.30% per year. And the median was 14.40% per year.

Back to Basics: PB Ratio


Cara Therapeutics PB Ratio Historical Data

The historical data trend for Cara Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cara Therapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
PB Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 4.61 3.85 4.03 3.03

Cara Therapeutics Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
PB Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.69 4.67 3.03 4.71 3.51

Competitive Comparison

For the Biotechnology subindustry, Cara Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Cara Therapeutics PB Ratio Distribution

For the Biotechnology industry and Healthcare sector, Cara Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Cara Therapeutics's PB Ratio falls into.



Cara Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Cara Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Jun. 2021)
=12.89/4.062
=3.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Cara Therapeutics  (NAS:CARA) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Cara Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Cara Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cara Therapeutics Business Description

Cara Therapeutics logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Traded in Other Exchanges
Address
107 Elm Street, 9th Floor, 4 Stamford Plaza, Stamford, CT, USA, 06902
Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.
Executives
Goncalves Joana officer: Chief Medical Officer C/O CARA THERAPEUTICS, INC. 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL STAMFORD CT 06902
Reilly Thomas Charles officer: Chief Financial Officer C/O CARA THERAPEUTICS, INC. 4 STAMFORD PLAZA, 107 ELM STREET STAMFORD CT 06902
Chalmers Derek T director, officer: President & CEO C/O CARA THERAPEUTICS, INC. 1 PARROTT DRIVE SHELTON CT 06484
Shiff Susan Ph.d. director C/O CARA THERAPEUTICS, INC. 4 STAMFORD PLAZA, 107 ELM STREET 9TH FL STAMFORD CT 06902
Vogelbaum Martin director 675 ALMANOR AVE SUNNYVALE CA 94085
Bains Harrison M Jr director PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: BAINS HARRISON M JR a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Ives Jeffrey L. director C/O CARA THERAPEUTICS, INC. 1 PARROTT DRIVE SHELTON CT 06484
Posner Christopher director C/O CARA THERAPEUTICS, INC. 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL STAMFORD CT 06902
Menzaghi Frederique Ph.d. officer: Chief Scientific Off,SVP-R&D C/O CARA THERAPEUTICS, INC. 1 PARROTT DRIVE SHELTON CT 06484
Makara Richard officer: VP, Head of Accting;Controller C/O CARA THERAPEUTICS, INC. 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL STAMDFORD CT 06902
Mohindru Mani officer: CFO & Chief Strategy Officer C/O CARA THERAPEUTICS, INC. 4 STAMFORD PLAZA, 107 ELM STREET STAMFORD CT 06902
Stauffer Joseph William officer: Chief Medical Officer 57 DURHAM ROAD SKILLMAN NJ 08558
Schoell Josef officer: Chief Financial Officer C/O CARA THERAPEUTICS, INC. 1 PARROTT DRIVE SHELTON CT 06484
Slagel Dean director C/O ESPERANTE VENTURES PO BOX 30127 LIMHAMN V7 SE-20061
Ruch Joshua 10 percent owner 4 DUNE ROAD EAST QUOGUE NY 11942

Cara Therapeutics Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)